March 29, 2024, 12:17:31 AM *
Welcome, Guest. Please login or register.

Login with username, password and session length
News: NEW CHILD BOARD CREATED IN THE POLITICAL SECTION FOR THE 2016 ELECTION
 
   Home   Help Login Register  
Pages: 1   Go Down
  Print  
Author Topic: Urgent Digitek Digoxin Recall  (Read 3581 times)
0 Members and 1 Guest are viewing this topic.
klaasend
Administrator
Monkey Mega Star
*
Offline Offline

Posts: 74276



WWW
« on: May 14, 2008, 11:14:31 PM »

Urgent Digitek Digoxin Recall
April 28, 2008
A class I recall is being issued on all Digitek (digoxin) tablets, which may contain twice the approved level of digoxin.The existence of double-strength pills pose a risk of digitalis toxicity, which can result in nausea, vomiting, low blood pressure, cardiac instability, bradycardia and even death.

Digitek is a registered trademark of Actavis Totowa (formerly Amide Pharmaceutical, Inc.) for their digoxin tablets, which are prescribed to treat heart failure and abnormal heart rhythms. The drug is distributed by Mylan Pharmaceuticals Inc., under a “Bertek” label and by UDL Laboratories, Inc. under a “UDL” label.

Patients taking Digitek should contact their physician immediately for medical advice. Retailers who carry Digitek should return the product to the place of purchase. Overdosing on this drug can be very dangerous. In fact, it digoxin was used in a series of murders in the 1980’s and 90’s that were committed by a male nurse who claimed to have killed the patients to “end their suffering”. More on these digoxin murders.

Contrary to many rumors, Actavis states that Digitek is manufactured in New Jersey - not China.
For more information visit: www.actavis.us .

Editor’s Note on Possible Class Action or Mass Tort Lawsuit:
Given the overwhelming response in the comments below and in people filling out our attorney-contact form, we have began releasing information (at the request of the injured) to a pharmaceutical injury attorney who is working on building a case for the victims of this recall. There may be grounds for legal reconciliation in some cases. Please fill out our contact form and we will ensure that your email gets evaluated by an experienced attorney who specializes in these kinds of cases. Don’t forget to leave your contact information and as many details as possible about your experience with Digitek (Digoxin) over the last few months. Be honest and complete in your answers in order for an attorney to better develop your case. In the meantime, discuss the Digitek recall, and your symptoms, with a physician to determine the best course of action for your health and wellbeing.

Logged
klaasend
Administrator
Monkey Mega Star
*
Offline Offline

Posts: 74276



WWW
« Reply #1 on: May 14, 2008, 11:17:07 PM »

http://www.actavis.us/en/media+center/newsroom/articles/digitek+digitex+recall+faq.htm

Press releases
09.05.2008 / Product

Digitek® recall – customer support and frequently asked questionsOn April 25, Actavis Totowa LLC initiated a Class 1 nationwide recall of Digitek® (digoxin tablets, USP, all strengths) for oral use. The products, manufactured by Actavis, are distributed by Mylan Pharmaceuticals, Inc. under the "Bertek" label and by UDL Laboratories, Inc. under the "UDL" label.

Press release from April 25

Acting together with Actavis to enact the recall of the product, Mylan Pharmaceuticals, Inc. as the distributor of Digitek, retained Stericycle customer service center (tel. 1-888-276-6166) to act as the recall coordinator immediately following Actavis’ decision to recall the product.

Please direct all inquiries you may have regarding this recall to Stericycle for proper handling and distribution.

Representatives at the service center are available to support all consumer queries and to provide direction on how to return your product.

If you have any questions about your treatment, or any medical inquiries regarding the product or possible substitutes, you should contact your physician immediately.

Frequently asked questions:


Q: Why is Actavis recalling Digitek® (digoxin)?
A: This voluntary all-lot recall is due to the possibility that some tablets with double the appropriate thickness may have been commercially released. These tablets may contain twice the approved level of active ingredient than is appropriate.


Q: What should I do if I’m taking Digitek® (digoxin)?
A: Patients should contact their physician to get a new prescription. All inquiries related to returning your product or the recall should be addressed to Stericycle customer service at 1-888-276-6166 (option 1 for consumers or option 2 for wholesalers/distributors and retailers.
Representatives are available Monday through Friday, 8 am to 5 pm EST.


Q: How can I report serious side effects from, or reactions to, digoxin?
A: If you wish to report an adverse experience from taking digoxin, you are directed to select option “3” from the menu provided on the Stericycle answering service where you will be directed to an Actavis representative who will process your information.
We also report such incidences to the FDA in accordance with Federal Regulations. Please call customer service at 1-888-276-6166, extension 3.
Representatives are available Monday through Friday, 8 am to 5 pm EST.
If you need medical attention or have any inquiries regarding your treatment, however, you should contact your physician.


Q: What is Digitek® (digoxin)?
A: Digitek is the brand name for digoxin tablets, USP 0.125 mg and 0.25 mg, manufactured by Actavis and distributed by Mylan Pharmaceuticals, Inc. under the Bertek and UDL labels. It is prescribed for oral use to treat heart failure and abnormal heart rhythms.


Q: Where is Digitek® (digoxin) manufactured?
A: Digitek is manufactured in the United States by Actavis Totowa, in New Jersey.


Q: Is the recall just in the United States, or also in other countries?
A: The recall is only in the United States.


Media contact:
Hjordis Arnadottir
Director, External Communications
Email: harnadottir@actavis.com
Tel.: +1 (973) 889-6686



Press releases
25.04.2008 / Product

Actavis Totowa (formerly known as Amide Pharmaceutical, Inc.) recalls all lots of Bertek and UDL Laboratories Digitek (digoxin tablets, USP) as a precaution
Morristown, NJ, 25 April, 2008 - Actavis Totowa LLC, a United States manufacturing division of the international generic pharmaceutical company Actavis Group, is initiating a Class 1 nationwide recall of Digitek (digoxin tablets, USP, all strengths) for oral use.  The products are distributed by Mylan Pharmaceuticals, Inc. under a "Bertek" label and by UDL Laboratories, Inc. under a "UDL" label.

The voluntary all-lot recall is due to the possibility that tablets with double the appropriate thickness may have been commercially released.  These tablets may contain twice the approved level of active ingredient than is appropriate. 

Digitek is used to treat heart failure and abnormal heart rhythms.  The existence of double-strength tablets poses a risk of digitalis toxicity in patients with renal failure.  Digitalis toxicity can cause nausea, vomiting, dizziness, low blood pressure, cardiac instability and bradycardia. Death can also result from excessive Digitalis intake.  Several reports of illness and injuries have been received. 

Actavis manufactures the products for Mylan and the products are distributed by Mylan and UDL under the Bertek and UDL labels.  Bertek and UDL are affiliates of Mylan.

Any customer inquiries related to this action should be addressed to Stericycle customer service at 1-888-276-6166 with representatives available Monday through Friday, 8 am to 5 pm EST.  Additional information about the voluntary recall can also be found at www.actavis.us.

Retailers who have this product are urged to return the product to their place of purchase.  If consumers have medical questions, they should contact their health care providers.

This recall is being conducted with the knowledge of the Food and Drug Administration.

Any adverse reactions experienced with the use of this product, and/or quality problems should also be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at  MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.



Media contact:
Hjordis Arnadottir
Director, External Communications
Email: harnadottir@actavis.com
Tel.: +1 (973) 889-6686


Logged
Pages: 1   Go Up
  Print  
 
Jump to:  

Use of this web site in any manner signifies unconditional acceptance, without exception, of our terms of use.
Powered by SMF 1.1.13 | SMF © 2006-2011, Simple Machines LLC
 
Page created in 6.235 seconds with 19 queries.